title: [Survival prognosis in ovarian carcinoma Figo stages III and IV: 1980-1985 versus 1986-1993. A comparison of 2 treatment periods].
abstract: We examined the survival prognosis of 638 patients who had ovarian carcinoma Figo stages III and IV. We considered two separate time periods, 1980-1985 versus 1986-1993, including the size of the postoperative residual tumor, polychemotherapy with and without platinum, histological grading 1 versus 2 and 3, Figo stage III versus IV, and ascites present versus no ascites. Since 1986, 96% of the patients received platinum-containing polychemotherapy at a dosage of > or = 75 mg/m2, whereas between 1980 and 1985, only 76% of these patients received platinum-containing polychemotherapy at a dosage of 50 mg/m2, and 24% of the patients received polychemotherapy without platinum. The size of residual tumor masses and also the time period of treatment had an independent influence on survival prognosis. Patients treated from 1980 to 1985 had a relative risk to die which was 1.44 times higher than for the patients who were studied from 1986 to 1993.
authors.affiliation: Abteilung für Geburtshilfe und Gynäkologie, Universitäts-Frauenklinik Wien, Osterreich.
authors.forename: G
authors.initials: G
authors.lastname: Knappitsch
authors.forename: K
authors.initials: K
authors.lastname: Gruböck
authors.forename: H
authors.initials: H
authors.lastname: Salzer
authors.forename: A
authors.initials: A
authors.lastname: Kaider
authors.forename: C
authors.initials: C
authors.lastname: Kurz
authors.forename: N
authors.initials: N
authors.lastname: Vavra
authors.forename: P
authors.initials: P
authors.lastname: Speiser
authors.forename: P
authors.initials: P
authors.lastname: Sevelda
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D017671:Platinum Compounds / Q000008:administration & dosage; D012189:Retrospective Studies; D012306:Risk; D015996:Survival Rate
chemical_list: D017671:Platinum Compounds
vernacular_title: Uberlebensprognose bei Ovarialkarzinomen in den Figo-Stadien III und IV: 1980-1985 versus 1986-1993. Ein Vergleich zweier Behandlungsperioden.